Alnylam Pharmaceuticals Deal History & Licensing Activity

About Alnylam Pharmaceuticals Licensing & Deal Activity

Alnylam Pharmaceuticals is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 12 deals over the past three years, Alnylam Pharmaceuticals ranks among the most acquisitive companies tracked by Ambrosia Ventures.

Key therapeutic areas of focus for Alnylam Pharmaceuticals include Cardiovascular (15 deals and trials), Mega Deals (12 deals and trials), CNS Disorders (5 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Alnylam Pharmaceuticals has shown particular interest in oligonucleotides, rnai, gene therapy.

Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alnylam Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Alnylam Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.